Loading...
•
Dec 31, 2024
Iovance Q4 2024 Earnings Report
Iovance Biotherapeutics, Inc. reported its financial results and corporate updates for the fourth quarter and full year 2024.
Key Takeaways
Iovance Biotherapeutics successfully drove strong early adoption for its U.S. commercial launch of Amtagvi®, achieving the upper end of its FY24 guidance range. The company reported total product revenue of $73.7 million for Q4 2024 and $164.1 million for FY24, with significant growth in Amtagvi and Proleukin sales. Net loss for Q4 2024 was $78.6 million, a notable improvement from the previous year.
Total product revenue for Q4 2024 was $73.7 million, driven by Amtagvi and Proleukin sales.
Amtagvi revenue for Q4 2024 was $48.7 million, reflecting strong adoption and increasing demand.
Net loss for Q4 2024 improved to $78.6 million, or $0.26 per share, compared to $116.4 million, or $0.45 per share, in Q4 2023.
Cash, cash equivalents, and investments stood at approximately $422 million as of February 26, 2025, expected to fund operations into the second half of 2026.
Revenue by Segment
Forward Guidance
Iovance is reaffirming its total product revenue guidance for FY25 and anticipates significant growth, with regulatory approvals expected in new markets and continued acceleration of Amtagvi adoption.
Positive Outlook
- Reaffirming FY25 total product revenue guidance of $450M-$475M.
- FY25 cash burn anticipated to be under $300M.
- 2025 regulatory approvals for Amtagvi expected in the UK, EU, and Canada.
- Enrollment accelerating across global registrational trials in frontline advanced melanoma and previously treated advanced NSCLC.
- Gross margins are expected to increase over time and surpass 70% over the next several years.
Challenges Ahead
- No specific negative forward guidance points were highlighted in the provided text.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...